Value of serum tumor markers on assessing therapy efficacy in treatment of advanced non-small cell lung cancer
Ji Decheng
Abstract：Objective To investigate the value of serum tumor markers on assessing therapy efficacy in treatment of advanced non-small cell lung.Methods Totally 93 patients with advanced non small cell lung cancer from March 2013 to March 2015 were enrolled.Before and 2 months after treatment,the tumor markers including carcinoembryonic antigen (CEA),carbohydrate antigen 125 (CA125),cytokerantin-19-fragment (Cyfra21-1) and squamous cell carcinoma antigen (SCCAg),neuron-specific enolase (NSE) were measured.Results The effective rate was 49.5％ (46/93).According to the outcomes,the patients were divided into effective group (46 cases) and ineffective group (47 cases).Before treatment,the levels of serum tumor markers were not statistically different (P ＞0.05).After treatment,the levels of CEA,CA125,Cyfra21-1,SCCAg and NSE in effective group were significantly lower than those before treatment and those in control group at the same time points [(11 ± 9) μg/L vs (36±20),(37±19) μg/L,(30±13) kU/L vs (57±13),(61 ±14) kU/L,(2.2±1.1) μg/Lvs (8.7±4.9),(9.6±4.4) μg/L,(0.83±0.21) μg/L vs (1.36±0.66),(1.22±0.85) μg/L,(11.9±2.2) μg/L vs (18.4±1.9),(19.3 ±3.9) μg/L] (P＜0.05).Conclusion Serum tumor markers such as CEA,CA125,Cyfra21-1,SCCAg and NSE can evaluate the effect of therapy on advanced non-small cell lung cancer.
Keywords：Carcinoma,non-small cell lungSerum tumor markersTargeted therapy
Publication Date：2016-02-28
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 199-202 )